Sign In
Buy ROIV
$33.91
-0.610 (-1.77%)
At Close: Jul 31, 2026
Bank of Nova Scotia Cuts Stake in Roivant Sciences Ltd. $ROIV
05:15am, Saturday, 25'th Jul 2026
Bank of Nova Scotia cut its stake in Roivant Sciences Ltd. (NASDAQ: ROIV) by 7.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The ins
Allspring Global Investments Holdings LLC Buys New Stake in Roivant Sciences Ltd. $ROIV
04:21am, Saturday, 25'th Jul 2026
Allspring Global Investments Holdings LLC purchased a new stake in Roivant Sciences Ltd. (NASDAQ: ROIV) in the undefined quarter, according to its most recent filing with the SEC. The institutional in
DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, Augus
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
04:05pm, Thursday, 23'rd Jul 2026
BASEL, Switzerland and LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, A
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years?
06:15am, Tuesday, 07'th Jul 2026
Roivant Sciences anticipates three commercial launches over the next few years, led by brepocitinib. The stock is arguably expensive now, even with aggressive revenue estimates for 2031.
Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
08:22pm, Tuesday, 09'th Jun 2026
Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
06:32pm, Wednesday, 03'rd Jun 2026
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
05:24pm, Friday, 29'th May 2026
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy
01:09pm, Thursday, 21'st May 2026
Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered stron
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
06:20pm, Wednesday, 20'th May 2026
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
Roivant Sciences Q4 Earnings Call Highlights
10:08am, Wednesday, 20'th May 2026
Roivant Sciences NASDAQ: ROIV executives used the company's fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary h
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
09:15am, Wednesday, 20'th May 2026
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.26.
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
07:00am, Wednesday, 20'th May 2026
BASEL, Switzerland and LONDON and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, a
Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why
01:01pm, Tuesday, 19'th May 2026
Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
04:50pm, Wednesday, 13'th May 2026
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
